CHT101 / Nanjing Calmhome Cell & Gene Engineering Institute, Nanjing Miracle Biotechnology - LARVOL DELTA

A Clinical Study to Evaluate CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematologic Malignancies (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Nanjing Miracle Biotechnology Co., Ltd.

New P1 trial • Acute Lymphocytic Leukemia • Chronic Lymphocytic Leukemia • Classical Hodgkin Lymphoma • Hematological Malignancies • Oncology • ALK

A Phase I, Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematological Malignancies (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Nanjing Miracle Biotechnology Co., Ltd.

New P1 trial • Classical Hodgkin Lymphoma • Hematological Malignancies • Oncology • ALK

Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Trial primary completion date: Feb 2026 ➔ Mar 2027

Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN） (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

New P1 trial • Brain Cancer • Oncology • Primary Central Nervous System Lymphoma • Solid Tumor

Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Universal CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

COURAGE: A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

New P1 trial • Cutaneous T-cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

Metastases • New P1 trial • Oncology • Solid Tumor

A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Zhejiang University

New P1 trial • Cervical Cancer • Genito-urinary Cancer • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CD70